Cognitive Reappraisal for Suicide Prevention
(CRISP Trial)
Trial Summary
Do I have to stop taking my current medications for the trial?
The trial does not specify if you need to stop taking your current medications. However, patients who are on psychotropics and receiving community psychotherapy are included, so it seems you can continue your current medications.
What data supports the idea that Cognitive Reappraisal for Suicide Prevention is an effective treatment?
The available research shows that Cognitive Reappraisal for Suicide Prevention (CRISP) is effective for middle-aged and older adults who have been hospitalized for suicidal thoughts or attempts. CRISP helps by identifying personal triggers and teaching strategies to manage negative emotions, which can reduce suicidal thoughts. This approach is particularly important during the high-risk period after hospital discharge. Additionally, another study found that using cognitive reappraisal, as opposed to suppressing emotions, is linked to lower suicidal thoughts, suggesting that CRISP's focus on reappraisal is beneficial.12345
What safety data exists for Cognitive Reappraisal for Suicide Prevention?
The Cognitive Reappraisal Intervention for Suicide Prevention (CRISP) is a psychosocial intervention targeting cognitive reappraisal to reduce suicide risk in middle-aged and older adults recently hospitalized for suicidality. The intervention is based on identifying personalized triggers and negative emotions, providing strategies for adaptive responses. While the abstract does not provide specific safety data, it suggests that CRISP is designed to address a high-risk period post-discharge, indicating a focus on safety and prevention. Other studies mentioned, such as those on cognitive-based psychotherapy and dialectical behavior therapy, indicate that similar interventions are generally found to be feasible, acceptable, and potentially effective, though specific safety data for CRISP is not detailed in the provided abstracts.15678
Is the treatment Cognitive Reappraisal Intervention for Suicide Prevention (CRISP) a promising treatment?
What is the purpose of this trial?
The goal of this trial is to refine and test a novel emotion-regulation based psychosocial intervention designed to reduce suicide risk in middle-aged and older adults (50-90 years old) who have been discharged after a suicide-related hospitalization (i.e. for suicidal ideation or suicide attempt).
Research Team
Dimitris Kiosses, PhD
Principal Investigator
Weill Medical College of Cornell University
Eligibility Criteria
This trial is for adults aged 50-90 who have recently been hospitalized for suicidal thoughts or attempts. Participants must have a diagnosis of depression or anxiety, be on psychotropics, and receiving community psychotherapy. Excluded are those with psychotic disorders, bipolar I/II in manic states, dementia, severe medical issues, or language/sensory barriers.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
R61 Treatment
Certified social workers administer 12 weekly sessions of CRISP to participants after a suicide-related hospitalization
R61 Follow-up
Participants are assessed for target engagement with EEG assessments and cognitive reappraisal paradigm
R33 Treatment
Participants are randomized to CRISP or Supportive Therapy to evaluate cognitive reappraisal and suicide risk
R33 Follow-up
Participants are monitored for improvement in cognitive reappraisal ability and its association with suicide risk
Treatment Details
Interventions
- Cognitive Reappraisal Intervention for Suicide Prevention
- Supportive Therapy
Cognitive Reappraisal Intervention for Suicide Prevention is already approved in United States for the following indications:
- Suicide prevention in middle-aged and older adults
Find a Clinic Near You
Who Is Running the Clinical Trial?
Weill Medical College of Cornell University
Lead Sponsor
Stanford University
Collaborator
Florida State University
Collaborator
National Institute of Mental Health (NIMH)
Collaborator
Rutgers University
Collaborator